论文部分内容阅读
[目的]探究三九胃泰颗粒与奥美拉唑联用治疗功能性消化不良疗效和安全性。[方法]回顾性分析于我院就诊的功能性消化不良患者141例,根据治疗方法分为对照组47例、治疗组46例和联合用药组48例,对照组患者采用奥美拉唑与三九胃泰颗粒模拟剂治疗,治疗组采用奥美拉唑模拟剂和三九胃泰颗粒治疗,联合组采用奥美拉唑与三九胃泰颗粒治疗,观察比较三种方法治疗效果与不良反应发生情况。[结果]联合用药组总有效率为95.83%,显著高于治疗组和对照组的73.91%和72.34%;联合用药组的症状积分改善率为71.16%,显著高于治疗组(46.75%)和对照组(44.80%);治疗后,联合用药组患者的症状评分显著低于治疗组和对照组,以上差异均有统计学意义,P<0.05;三组不良反应分别为4.17%、6.52%和8.50%,差异不具有统计学意义,P>0.05。[结论]对于功能性消化不良患者,实施三九胃泰颗粒与奥美拉唑联合治疗,可改善患者临床症状,不良反应发生率较低,安全性较高,具有临床推广和应用价值。
[Objective] To investigate the efficacy and safety of Sanjiuweitai granule in combination with omeprazole in the treatment of functional dyspepsia. [Methods] A retrospective analysis of 141 patients with dysfunctional dyspepsia treated in our hospital was divided into control group (47 cases), treatment group (46 cases) and combination group (48 cases). The control group was treated with omeprazole and tris Jiweitai Granule Simulator treatment, the treatment group with omeprazole mimic agent and Sanjiuweitai granule treatment, the combination group with omeprazole and Sanjiuweitai granule treatment, the observation and comparison of the three methods of treatment and adverse reactions What happened? [Results] The total effective rate in combination group was 95.83%, which was significantly higher than 73.91% and 72.34% in treatment group and control group, 71.16% in combination group, significantly higher than that in treatment group (46.75%) and (44.80%). After treatment, the symptom score of the combination group was significantly lower than that of the treatment group and the control group, the difference was statistically significant (P <0.05); the adverse reactions were 4.17%, 6.52% and 8.50%, the difference was not statistically significant, P> 0.05. [Conclusion] For patients with functional dyspepsia, the combination of Sanjiuweitai Granules and omeprazole can improve the clinical symptoms, the incidence of adverse reactions is low, and the safety is high, which has the clinical popularization and application value.